The Department of Health and Human Services (HHS) released a report this week which details the Trump administration’s progress on lowering drug prices in relation to its pricing blueprint released in May, according to a Fierce Healthcare report.
HHS released the report 100 days after the original blueprint was released on May 11.
The agency, according to Fierce Healthcare, reported 60 percent less price hikes on brand drugs in same time frame last year and 54 percent more drops with generics and brand drugs.
Dan Best, senior advisor to HHS Secretary Alex Azar for pricing reform, said the moves are “unprecedented.”
Azar reportedly during a conference call with reporters said the changes show pharmaceutical companies see change on the horizon.
“They’re skating to where they see the puck is going,” he said. “They know we are about nothing short of the fundamental transformation of this entire segment of the economy: how drugs are priced and how they’re paid for.”
